ABOS vs AVTX
ABOS: Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients, with Phase 2 results expected in late 2026. AVTX: Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
Side-by-side fundamentals
| Metric | ABOS | AVTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.20 | $19.50 | |
| Market cap as of 2026-08-01 | $159M | $1.0B | |
| Net margin as of 2026-08-01 | -509.7% | -23254.2% | ABOS higher |
| Gross margin as of 2026-08-01 | n/a | +242.2% | |
| Operating margin as of 2026-08-01 | -550.0% | -33461.0% | ABOS higher |
| ROE as of 2026-08-01 | -123.1% | -77.8% | AVTX higher |
| ROA as of 2026-08-01 | -79.4% | -61.7% | AVTX higher |
| Debt / equity as of 2026-08-01 | 0.35 | 0.03 | AVTX lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | -86.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -85.2% | |
| Beta as of 2026-08-01 | 0.34 | 0.74 | |
| 1-year return as of 2026-07-27 close | +40.1% | +191.5% | AVTX higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.